Summary
Arsenic trioxide is an effective and indicated agent for relapsed acute promyelocytic leukemia (APL). A study now demonstrates that arsenic trioxide has clinical benefit for patients with newly diagnosed APL. This article reports findings from the study in which arsenic trioxide was given as consolidation therapy to patients with APL who had complete remission following standard induction therapy.
- Oncology Clinical Trials
- Leukemia
- © 2007 MD Conference Express